CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 100 enrolled
Drug / intervention
No Interventionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01568021
NCT01568021N/ACompleted

Post Market Surveillance of OZURDEX® for Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)

Allergan·observational·Posted Apr 2, 2012·Updated Feb 10, 2015

In Brief

An observational study evaluating No Intervention for Retinal Vein Occlusion and Macular Edema. Completed, enrolled 100 participants across 3 sites in 3 countries.

Detailed Summary

This multicenter observational study will assess the efficacy and tolerability of OZURDEX® in clinical practice, and will assess the time at which patients are considered for retreatment.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesDenmark, Norway, Sweden
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 2, 2012
Enrollment StartOct 1, 2011
Primary CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 14.3 years ago

Interventions

No Interventionother

No intervention was administered in this study.